SER — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Our grants and contracts reimburse us for direct and indirect costs relating to the grant projects and also provide us with a pre-negotiated profit margin on total direct and indirect costs of the grant award, excluding subcontractor costs, after giving effect to directly attributable costs and allo…

• The following table summarizes our results of operations for the three and six months ended June 30, 2026 and 2025 (in thousands):

• Research and development expenses were $7.0 million for the six months ended June 30, 2026, compared to $6.1 million for the same period in 2025. The increase of $0.9 million was primarily due to increases of $1.3 million in clinical related activities and $0.6 million in salaries, payroll related e…

• $0.3 million in consultant spend and a decrease of $0.3 million amortization for a prepaid technology access fee that was fully amortized in 2025.

• General and administrative expenses were $3.0 million for the three months ended June 30, 2026, compared to $2.5 million for the same period in 2025. The increase of $0.5 million was primarily driven by a $0.6 million increase legal expenses due to patent and financing activities and a $0.1 million …

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory, and other fees and services associated with maintaining compliance with the New York Stock Exchange Americ…

• The table presented below shows our operating expenses for the periods presented (in thousands):

• General and administrative expenses were $3.1 million for the three months ended March 31, 2026, compared to $2.9 million for the same period in 2025. The increase of $0.2 million was primarily driven by a $0.1 million increase in compensation expense, a $0.1 million increase in investor outreach ac…

• Other expense was $0.6 million for the three months ended March 31, 2026, compared to other income of $1.0 million for the same period in 2025. The $1.6 million increase in expense was primarily attributable to the non-cash loss on extinguishment of financial commitment assets and contingent warrant…

• See Note 5, Fair Value Measurements, and Note 6, Stockholders’ Equity (Deficit), to our unaudited condensed consolidated interim financial statements included elsewhere in this Report for additional information on fair value adjustments of associated to the tranche liabilities in connection with the…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• In the March 2026 PIPE, Gregory H. Bailey, M.D., a current member of our Board of Directors, acting as lead investor, and certain other investors, purchased shares of the Company’s common stock, pre-funded warrants, and redeemable warrants. As a result of this transaction, and following the receipt …

• The potential issuance of a substantial number of shares upon exercise of the redeemable warrants and other outstanding warrants, as well as the perception of future dilution or changes in control, could adversely affect the market price and volatility of our common stock and our ability to raise ad…

• Dr. Bailey and Juvenescence together hold a significant concentration of our common stock and are able to control or substantially influence matters requiring stockholder approval, which limits the ability of our other stockholders to influence corporate matters.

• As of August 10, 2026, Gregory H. Bailey, M.D., a member of our Board of Directors (“Board”) and Co‑Chairman of our Board, beneficially owned approximately 41% of our common stock (including shares issuable upon exercise of redeemable warrants held by him), and Juvenescence beneficially owned approx…

• As a result, Dr. Bailey and Juvenescence, if they act together, are able to control or substantially influence the election of our directors and the outcome of substantially all matters submitted to a vote of our stockholders, including the approval of mergers, amalgamations, sales of assets or othe…

Text removed vs the prior filing · source: 10-Q · 2026-05-14

• In the March 2026 PIPE, Gregory H. Bailey, M.D., a current member of our Board of Directors, acting as lead investor, and certain other investors, purchased shares of the Company’s common stock, pre-funded warrants, and redeemable warrants. As a result of this transaction, and subject to stockholder…

• Further, the issuance of shares to Dr. Bailey requires stockholder approval under NYSE American rules. If such approval is not obtained in a timely manner, or at all, the anticipated issuance of shares underlying the pre‑funded warrants will be delayed or may not occur, which could negatively affect…

• The potential issuance of a substantial number of shares upon exercise of the pre‑funded warrants and redeemable warrants, as well as the perception of future dilution or changes in control, could adversely affect the market price and volatility of our common stock and our ability to raise additiona…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• (1) Except as indicated by footnote, each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” is intended to satisfy the affirmative defense of Rule 10b5-1(c), as amended (the “Rule”).

• (2) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of the completion of all purchases or sales or the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permitte…